Search results
What You Should Know About Medications for Osteoporosis
Verywell Health via Yahoo News· 1 year agoMedically reviewed by Stella Bard, MD There are many medication options to treat osteoporosis, a...
Amgen (AMGN) Q4 Earnings Top, Horizon Drugs Drive Sales
Zacks via Yahoo Finance· 3 months agoAmgen AMGN reported fourth-quarter 2023 adjusted earnings of $4.71 per share, which beat the Zacks...
Can Amgen (AMGN) Keep the Beat Streak Alive in Q4 Earnings?
Zacks via Yahoo Finance· 4 months agoVolume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is...
Amgen Sweetens Full-Year Outlook After Narrowly Beating Third-Quarter Forecasts
Investor's Business Daily· 2 years agoAmgen stock popped Friday after the drugmaker sweetened its 2022 outlook following a third-quarter...
Amgen (AMGN) Q2 Earnings Beat Estimates, 2023 View Raised
Zacks via Yahoo Finance· 9 months agoAmgen AMGN reported second-quarter 2023 earnings of $5.00 per share, which beat the Zacks Consensus...
Amgen (AMGN) to Report Q2 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 9 months agoVolume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is...
Why Is Amgen (AMGN) Down 4.2% Since Last Earnings Report?
Zacks via Yahoo Finance· 1 year agoIt has been about a month since the last earnings report for Amgen (AMGN). Shares have lost about...
Amgen Is 'Confident' It Can Wrap The Horizon Takeover By December
Investor's Business Daily· 9 months agoAmgen stock jumped Friday after the biotech behemoth broadly topped Wall Street's second-quarter...
Amgen (AMGN) Stock Outperforms Industry YTD: Here's Why
Zacks via Yahoo Finance· 8 months agoAmgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to be offset...
Amgen: Relative Valuation Remains Unattractive
GuruFocus.com via Yahoo Finance· 5 months agoAmgen Inc. (NASDAQ:AMGN) is an American biopharmaceutical company specializing in the development and commercialization of medicines aimed at treating...
